Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 5 April 2024, including: Genmab A/S buys into ADCs; Roivant Sciences set to take on AbbVie Inc. in uveitis; Ipsen SA signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda Therapeutics, Inc.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Genmab Adds To Sector ADC Buying Spree With $1.8bn ProfoundBio Acquisition" - Scrip, 3 Apr, 2024.)
(Also see "Roivant May Take On AbbVie In Uveitis With Strong Phase II Efficacy" - Scrip, 2 Apr, 2024.)
(Also see "Ipsen Dives Back Into Dealmaking With First ADC Pact" - Scrip, 2 Apr, 2024.)
(Also see "Window Of Opportunity: Korea Unveils Cutting-Edge Bio Initiative" - Scrip, 31 Mar, 2024.)
(Also see "All Over For Acorda After A Torrid Few Years" - Scrip, 3 Apr, 2024.)